Chemokines and chemokine receptors in mood disorders, schizophrenia, and cognitive impairment: A systematic review of biomarker studies

Neuroscience and Biobehavioral Reviews

Volumn 42, Issue , 2014, Pages 93-115

  Stuart, M J ^a,b   Baune, B T ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b JAMES COOK UNIVERSITY   (Australia)

Author keywords

Alzheimer's; Biomarker; Bipolar; Chemokine; Cognition; Cytokine; Depression; Hippocampus; Immune; Schizophrenia; Suicide

Indexed keywords

BIOLOGICAL MARKER; CHEMOKINE; CHEMOKINE RECEPTOR; FRACTALKINE; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; STROMAL CELL DERIVED FACTOR 1;

ALZHEIMER DISEASE; BIPOLAR DISORDER; BRAIN FUNCTION; CHEMOTAXIS; CHRONIC STRESS; CLINICAL RESEARCH; COGNITIVE DEFECT; DEPRESSION; DISEASE ASSOCIATION; HUMAN; ILLNESS BEHAVIOR; MILD COGNITIVE IMPAIRMENT; MOOD DISORDER; NEUROMODULATION; NEUROPATHOLOGY; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SCHIZOPHRENIA; SUICIDE; SYSTEMATIC REVIEW; TRANSLATIONAL RESEARCH; ANIMAL; METABOLISM;

ANIMALS; BIOLOGICAL MARKERS; CHEMOKINES; COGNITION DISORDERS; HUMANS; MOOD DISORDERS; RECEPTORS, CHEMOKINE; SCHIZOPHRENIA;

EID: 84896055808     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2014.02.001     Document Type: Review

References (218)

1. Altamura A.C., Mundo E., Cattaneo E., Pozzoli S., Dell'osso B., Gennarelli M., Vergani C., Trabattoni D., Arosio B., Clerici M. The MCP-1 gene (SCYA2) and mood disorders: preliminary results of a case-control association study. Neuroimmunomodulation 2010, 17:126-131.
2. Andjelkovic A.V., Song L., Dzenko K.A., Cong H., Pachter J.S. Functional expression of CCR2 by human fetal astrocytes. J. Neurosci. Res. 2002, 70:219-231.
3. Balistreri C.R., Grimaldi M.P., Vasto S., Listi F., Chiappelli M., Licastro F., Lio D., Caruso C., Candore G. Association between the polymorphism of CCR5 and Alzheimer's disease: results of a study performed on male and female patients from Northern Italy. Ann. N. Y. Acad. Sci. 2006, 1089:454-461.
4. Balu D.T., Coyle J.T. Neuroplasticity signaling pathways linked to the pathophysiology of schizophrenia. Neurosci. Biobehav. Rev. 2011, 35:848-870.
5. Banisadr G., Fontanges P., Haour F., Kitabgi P., Rostene W., Melik Parsadaniantz S. Neuroanatomical distribution of CXCR4 in adult rat brain and its localization in cholinergic and dopaminergic neurons. Eur. J. Neurosci. 2002, 16:1661-1671.
6. Banisadr G., Gosselin R.D., Mechighel P., Rostene W., Kitabgi P., Melik Parsadaniantz S. Constitutive neuronal expression of CCR2 chemokine receptor and its colocalization with neurotransmitters in normal rat brain: functional effect of MCP-1/CCL2 on calcium mobilization in primary cultured neurons. J. Comp. Neurol. 2005, 492:178-192.
7. Banisadr G., Queraud-Lesaux F., Boutterin M.C., Pelaprat D., Zalc B., Rostene W., Haour F., Parsadaniantz S.M. Distribution, cellular localization and functional role of CCR2 chemokine receptors in adult rat brain. J. Neurochem. 2002, 81:257-269.
8. Barbosa I.G., Rocha N.P., Bauer M.E., de Miranda A.S., Huguet R.B., Reis H.J., Zunszain P.A., Horowitz M.A., Pariante C.M., Teixeira A.L. Chemokines in bipolar disorder: trait or state?. Eur. Arch. Psychiatry Clin. Neurosci. 2013, 263:159-165.
9. Baune B. Conceptual challenges of a tentative model of stress-induced depression. PLoS One 2009, 4:e4266.
10. Baune B.T., Miller R., McAfoose J., Johnson M., Quirk F., Mitchell D. The role of cognitive impairment in general functioning in major depression. Psychiatry Res. 2010, 176:183-189.
11. Baune B.T., Smith E., Reppermund S., Air T., Samaras K., Lux O., Brodaty H., Sachdev P., Trollor J.N. Inflammatory biomarkers predict depressive, but not anxiety symptoms during aging: the prospective Sydney Memory and Aging Study. Psychoneuroendocrinology 2012, 37:1521-1530.
12. Baune B.T., Stuart M., Gilmour A., Wersching H., Heindel W., Arolt V., Berger K. The relationship between subtypes of depression and cardiovascular disease: a systematic review of biological models. Transl. Psychiatry 2012, 2:e92.
13. Beumer W., Drexhage R.C., De Wit H., Versnel M.A., Drexhage H.A., Cohen D. Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome. Psychoneuroendocrinology 2012, 37:1901-1911.
14. Blasko I., Lederer W., Oberbauer H., Walch T., Kemmler G., Hinterhuber H., Marksteiner J., Humpel C. Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias. Dement. Geriatr. Cogn. Disord. 2006, 21:9-15.
15. Bonotis K., Krikki E., Holeva V., Aggouridaki C., Costa V., Baloyannis S. Systemic immune aberrations in Alzheimer's disease patients. J. Neuroimmunol. 2008, 193:183-187.
16. Bradley A.J., Dinan T.G. A systematic review of hypothalamic-pituitary-adrenal axis function in schizophrenia: implications for mortality. J. Psychopharmacol. (Oxford, England) 2010, 24:91-118.
17. Breen E.C., Reynolds S.M., Cox C., Jacobson L.P., Magpantay L., Mulder C.B., Dibben O., Margolick J.B., Bream J.H., Sambrano E., Martinez-Maza O., Sinclair E., Borrow P., Landay A.L., Rinaldo C.R., Norris P.J. Multisite comparison of high-sensitivity multiplex cytokine assays. Clin. Vaccine Immunol. 2011, 18:1229-1242.
18. Brennand K.J., Simone A., Jou J., Gelboin-Burkhart C., Tran N., Sangar S., Li Y., Mu Y., Chen G., Yu D., McCarthy S., Sebat J., Gage F.H. Modelling schizophrenia using human induced pluripotent stem cells. Nature 2011, 473:221-225.
19. Brietzke E., Kauer-Sant'Anna M., Teixeira A.L., Kapczinski F. Abnormalities in serum chemokine levels in euthymic patients with bipolar disorder. Brain Behav. Immun. 2009, 23:1079-1082.
20. Brown A.S., Hooton J., Schaefer C.A., Zhang H., Petkova E., Babulas V., Perrin M., Gorman J.M., Susser E.S. Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring. Am. J. Psychiatry 2004, 161:889-895.
21. Buka S.L., Tsuang M.T., Torrey E.F., Klebanoff M.A., Wagner R.L., Yolken R.H. Maternal cytokine levels during pregnancy and adult psychosis. Brain Behav. Immun. 2001, 15:411-420.
22. Campbell S.J., Meier U., Mardiguian S., Jiang Y., Littleton E.T., Bristow A., Relton J., Connor T.J., Anthony D.C. Sickness behaviour is induced by a peripheral CXC-chemokine also expressed in multiple sclerosis and EAE. Brain Behav. Immun. 2010, 24:738-746.
23. Chintawar S., Cayrol R., Antel J., Pandolfo M., Prat A. Blood-brain barrier promotes differentiation of human fetal neural precursor cells. Stem Cells 2009, 27:838-846.
24. Choi C., Jeong J.H., Jang J.S., Choi K., Lee J., Kwon J., Choi K.G., Lee J.S., Kang S.W. Multiplex analysis of cytokines in the serum and cerebrospinal fluid of patients with Alzheimer's disease by color-coded bead technology. J. Clin. Neurol. 2008, 4:84-88.
25. Christa Maree Stephan B., Minett T., Pagett E., Siervo M., Brayne C., McKeith I.G. Diagnosing Mild Cognitive Impairment (MCI) in clinical trials: a systematic review. BMJ Open 2013, 3.
26. Combarros O., Infante J., Llorca J., Berciano J. No evidence for association of the monocyte chemoattractant protein-1 (-2518) gene polymorphism and Alzheimer's disease. Neurosci. Lett. 2004, 360:25-28.
27. Combarros O., Infante J., Llorca J., Pena N., Fernandez-Viadero C., Berciano J. The chemokine receptor CCR5-Delta32 gene mutation is not protective against Alzheimer's disease. Neurosci. Lett. 2004, 366:312-314.
28. Corona A.W., Huang Y., O'Connor J.C., Dantzer R., Kelley K.W., Popovich P.G., Godbout J.P. Fractalkine receptor (CX3CR1) deficiency sensitizes mice to the behavioral changes induced by lipopolysaccharide. J. Neuroinflammation 2010, 7:93.
29. Corona A.W., Norden D.M., Skendelas J.P., Huang Y., O'Connor J.C., Lawson M., Dantzer R., Kelley K.W., Godbout J.P. Indoleamine 2,3-dioxygenase inhibition attenuates lipopolysaccharide induced persistent microglial activation and depressive-like complications in fractalkine receptor (CX(3)CR1)-deficient mice. Brain Behav. Immun. 2013, 31:134-142.
30. Correa J.D., Starling D., Teixeira A.L., Caramelli P., Silva T.A. Chemokines in CSF of Alzheimer's disease patients. Arq. Neuropsiquiatr. 2011, 69:455-459.
31. Croitoru-Lamoury J., Guillemin G.J., Boussin F.D., Mognetti B., Gigout L.I., Cheret A., Vaslin B., Le Grand R., Brew B.J., Dormont D. Expression of chemokines and their receptors in human and simian astrocytes: evidence for a central role of TNF alpha and IFN gamma in CXCR4 and CCR5 modulation. Glia 2003, 41:354-370.
32. Danik M., Puma C., Quirion R., Williams S. Widely expressed transcripts for chemokine receptor CXCR1 in identified glutamatergic, gamma-aminobutyric acidergic, and cholinergic neurons and astrocytes of the rat brain: a single-cell reverse transcription-multiplex polymerase chain reaction study. J. Neurosci. Res. 2003, 74:286-295.
33. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 2008, 9:46-56.
34. Dantzer R., O'Connor J.C., Lawson M.A., Kelley K.W. Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology 2011, 36:426-436.
35. Dennison U., McKernan D., Cryan J., Dinan T. Schizophrenia patients with a history of childhood trauma have a pro-inflammatory phenotype. Psychol. Med. 2012, 1-7.
36. Di Nicola M., Cattaneo A., Hepgul N., Di Forti M., Aitchison K.J., Janiri L., Murray R.M., Dazzan P., Pariante C.M., Mondelli V. Serum and gene expression profile of cytokines in first-episode psychosis. Brain Behav. Immun. 2013, 31:90-95.
37. Di Prisco S., Merega E., Milanese M., Summa M., Casazza S., Raffaghello L., Pistoia V., Uccelli A., Pittaluga A. CCL5-glutamate interaction in central nervous system: early and acute presynaptic defects in EAE mice. Neuropharmacology 2013, 75:337-346.
38. Di Prisco S., Summa M., Chellakudam V., Rossi P.I., Pittaluga A. RANTES-mediated control of excitatory amino acid release in mouse spinal cord. J. Neurochem. 2012, 121:428-437.
39. Drexhage R.C., Hoogenboezem T.H., Versnel M.A., Berghout A., Nolen W.A., Drexhage H.A. The activation of monocyte and T cell networks in patients with bipolar disorder. Brain Behav. Immun. 2011, 25:1206-1213.
40. Drexhage R.C., Weigelt K., van Beveren N., Cohen D., Versnel M.A., Nolen W.A., Drexhage H.A. Immune and neuroimmune alterations in mood disorders and schizophrenia. Int. Rev. Neurobiol. 2011, 101:169-201.
41. Eller T., Vasar V., Shlik J., Maron E. Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder. Prog. Neuro-psychopharmacol. Biol. Psychiatry 2008, 32:445-450.
42. Eller T., Vasar V., Shlik J., Maron E. Effects of bupropion augmentation on pro-inflammatory cytokines in escitalopram-resistant patients with major depressive disorder. J. Psychopharmacol. (Oxford, England) 2009, 23:854-858.
43. Ellman L.M., Deicken R.F., Vinogradov S., Kremen W.S., Poole J.H., Kern D.M., Tsai W.Y., Schaefer C.A., Brown A.S. Structural brain alterations in schizophrenia following fetal exposure to the inflammatory cytokine interleukin-8. Schizophr. Res. 2010, 121:46-54.
44. Eltayeb S., Berg A.L., Lassmann H., Wallstrom E., Nilsson M., Olsson T., Ericsson-Dahlstrand A., Sunnemark D. Temporal expression and cellular origin of CC chemokine receptors CCR1, CCR2 and CCR5 in the central nervous system: insight into mechanisms of MOG-induced EAE. J. Neuroinflammation 2007, 4:14.
45. Erbagci A.B., Herken H., Koyluoglu O., Yilmaz N., Tarakcioglu M. Serum IL-1beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment. Mediators Inflamm. 2001, 10:109-115.
46. Eyre H., Baune B.T. Neuroplastic changes in depression: a role for the immune system. Psychoneuroendocrinology 2012, 37:1397-1416.
47. Favalli G., Li J., Belmonte-de-Abreu P., Wong A.H., Daskalakis Z.J. The role of BDNF in the pathophysiology and treatment of schizophrenia. J. Psychiatr. Res. 2012, 46:1-11.
48. Fenoglio C., Galimberti D., Lovati C., Guidi I., Gatti A., Fogliarino S., Tiriticco M., Mariani C., Forloni G., Pettenati C., Baron P., Conti G., Bresolin N., Scarpini E. MCP-1 in Alzheimer's disease patients: A-2518G polymorphism and serum levels. Neurobiol. Aging 2004, 25:1169-1173.
49. Fernandez-Egea E., Bruna A., Garcia-Rizo C., Bernardo M., Kirkpatrick B. Stem cell signaling in newly diagnosed, antipsychotic-naive subjects with nonaffective psychosis. Mol. Psychiatry 2009, 14:989-991.
50. Fillman S.G., Cloonan N., Catts V.S., Miller L.C., Wong J., McCrossin T., Cairns M., Weickert C.S. Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia. Mol. Psychiatry 2013, 18:206-214.
51. Finder V.H. Alzheimer's disease: a general introduction and pathomechanism. J. Alzheimer Dis. 2010, 22(Suppl. 3):5-19.
52. Flynn G., Maru S., Loughlin J., Romero I.A., Male D. Regulation of chemokine receptor expression in human microglia and astrocytes. J. Neuroimmunol. 2003, 136:84-93.
53. Galimberti D., Fenoglio C., Lovati C., Gatti A., Guidi I., Venturelli E., Cutter G.R., Mariani C., Forloni G., Pettenati C., Baron P., Conti G., Bresolin N., Scarpini E. CCR2-64I polymorphism and CCR5Delta32 deletion in patients with Alzheimer's disease. J. Neurol. Sci. 2004, 225:79-83.
54. Galimberti D., Fenoglio C., Lovati C., Venturelli E., Guidi I., Corra B., Scalabrini D., Clerici F., Mariani C., Bresolin N., Scarpini E. Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease. Neurobiol. Aging 2006, 27:1763-1768.
55. Galimberti D., Schoonenboom N., Scarpini E., Scheltens P., Dutch-Italian Alzheimer Research G. Chemokines in serum and cerebrospinal fluid of Alzheimer's disease patients. Ann. Neurol. 2003, 53:547-548.
56. Galimberti D., Schoonenboom N., Scheltens P., Fenoglio C., Bouwman F., Venturelli E., Guidi I., Blankenstein M.A., Bresolin N., Scarpini E. Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. Arch. Neurol. 2006, 63:538-543.
57. Galimberti D., Venturelli E., Fenoglio C., Lovati C., Guidi I., Scalabrini D., Mariani C., Bresolin N., Scarpini E. IP-10 serum levels are not increased in mild cognitive impairment and Alzheimer's disease. Eur. J. Neurol. 2007, 14:e3-e4.
58. Geppert A.M., Losy J., Przedpelska-Ober E., Kozubski W. CCL3 correlates with the number of mood disturbances and personality changes in patients with Alzheimer's disease. Psychiatry Res. 2010, 176:261-264.
59. Giovannelli A., Limatola C., Ragozzino D., Mileo A.M., Ruggieri A., Ciotti M.T., Mercanti D., Santoni A., Eusebi F. CXC chemokines interleukin-8 (IL-8) and growth-related gene product alpha (GROalpha) modulate Purkinje neuron activity in mouse cerebellum. J. Neuroimmunol. 1998, 92:122-132.
60. Girotti M., Donegan J.J., Morilak D.A. Chronic intermittent cold stress sensitizes neuro-immune reactivity in the rat brain. Psychoneuroendocrinology 2011, 36:1164-1174.
61. Goldstein B.I., Kemp D.E., Soczynska J.K., McIntyre R.S. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J. Clin. Psychiatry 2009, 70:1078-1090.
62. Gordon R.J., McGregor A.L., Connor B. Chemokines direct neural progenitor cell migration following striatal cell loss. Mol. Cell. Neurosci. 2009, 41:219-232.
63. Gould T.D., Einat H. Animal models of bipolar disorder and mood stabilizer efficacy: a critical need for improvement. Neurosci. Biobehav. Rev. 2007, 31:825-831.
64. Grassi-Oliveira R., Brieztke E., Teixeira A., Pezzi J.C., Zanini M., Lopes R.P., Bauer M.E. Peripheral chemokine levels in women with recurrent major depression with suicidal ideation. Rev. Bras. Psiquiatr. 2012, 34:71-75.
65. Gray J.A., Roth B.L. The pipeline and future of drug development in schizophrenia. Mol. Psychiatry 2007, 12:904-922.
66. Green M.J., Matheson S.L., Shepherd A., Weickert C.S., Carr V.J. Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis. Mol. Psychiatry 2011, 16:960-972.
67. Guillemin G.J., Croitoru-Lamoury J., Dormont D., Armati P.J., Brew B.J. Quinolinic acid upregulates chemokine production and chemokine receptor expression in astrocytes. Glia 2003, 41:371-381.
68. Halks-Miller M., Schroeder M.L., Haroutunian V., Moenning U., Rossi M., Achim C., Purohit D., Mahmoudi M., Horuk R. CCR1 is an early and specific marker of Alzheimer's disease. Ann. Neurol. 2003, 54:638-646.
69. Hallberg L., Janelidze S., Engstrom G., Wisen A.G., Westrin A., Brundin L. Exercise-induced release of cytokines in patients with major depressive disorder. J. Affect. Disord. 2010, 126:262-267.
70. Harries L.W., Bradley-Smith R.M., Llewellyn D.J., Pilling L.C., Fellows A., Henley W., Hernandez D., Guralnik J.M., Bandinelli S., Singleton A., Ferrucci L., Melzer D. Leukocyte CCR2 expression is associated with mini-mental state examination score in older adults. Rejuvenation Res. 2012, 15:395-404.
71. Hashimoto K. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res. Rev. 2009, 61:105-123.
72. He D., Zhang Y., Dong S., Wang D., Gao X., Zhou H. Pharmacological treatment for memory disorder in multiple sclerosis. Cochrane Database Syst. Rev. 2013, 12:CD008876.
73. Heinisch S., Kirby L.G. Fractalkine/CX3CL1 enhances GABA synaptic activity at serotonin neurons in the rat dorsal raphe nucleus. Neuroscience 2009, 164:1210-1223.
74. Heinisch S., Kirby L.G. SDF-1alpha/CXCL12 enhances GABA and glutamate synaptic activity at serotonin neurons in the rat dorsal raphe nucleus. Neuropharmacology 2010, 58:501-514.
75. Hellmann-Regen J., Piber D., Hinkelmann K., Gold S.M., Heesen C., Spitzer C., Endres M., Otte C. Depressive syndromes in neurological disorders. Eur. Arch. Psychiatry Clin. Neurosci. 2013, 263(Suppl. 2):S123-S136.
76. Hinojosa A.E., Garcia-Bueno B., Leza J.C., Madrigal J.L. CCL2/MCP-1 modulation of microglial activation and proliferation. J. Neuroinflammation 2011, 8:77.
77. Hochstrasser T., Marksteiner J., Defrancesco M., Deisenhammer E.A., Kemmler G., Humpel C. Two blood monocytic biomarkers (CCL15 and p21) combined with the mini-mental state examination discriminate Alzheimer's disease patients from healthy subjects. Dement. Geriatr. Cogn. Dis. Extra 2011, 1:297-309.
78. Howes O.D., Kapur S. The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr. Bull. 2009, 35:549-562.
79. Hu W.T., Chen-Plotkin A., Arnold S.E., Grossman M., Clark C.M., Shaw L.M., Pickering E., Kuhn M., Chen Y., McCluskey L., Elman L., Karlawish J., Hurtig H.I., Siderowf A., Lee V.M., Soares H., Trojanowski J.Q. Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. Acta Neuropathol. (Berl.) 2010, 119:669-678.
80. Huerta C., Alvarez V., Mata I.F., Coto E., Ribacoba R., Martinez C., Blazquez M., Guisasola L.M., Salvador C., Lahoz C.H., Pena J. Chemokines (RANTES and MCP-1) and chemokine-receptors (CCR2 and CCR5) gene polymorphisms in Alzheimer's and Parkinson's disease. Neurosci. Lett. 2004, 370:151-154.
81. Hyman S.E. Can neuroscience be integrated into the DSM-V?. Nat. Rev. Neurosci. 2007, 8:725-732.
82. Iarlori C., Gambi D., Gambi F., Lucci I., Feliciani C., Salvatore M., Reale M. Expression and production of two selected beta-chemokines in peripheral blood mononuclear cells from patients with Alzheimer's disease. Exp. Gerontol. 2005, 40:605-611.
83. Imitola J., Raddassi K., Park K.I., Mueller F.J., Nieto M., Teng Y.D., Frenkel D., Li J., Sidman R.L., Walsh C.A., Snyder E.Y., Khoury S.J. Directed migration of neural stem cells to sites of CNS injury by the stromal cell-derived factor 1alpha/CXC chemokine receptor 4 pathway. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:18117-18122.
84. Isung J., Aeinehband S., Mobarrez F., Martensson B., Nordstrom P., Asberg M., Piehl F., Jokinen J. Low vascular endothelial growth factor and interleukin-8 in cerebrospinal fluid of suicide attempters. Transl. Psychiatry 2012, 2:e196.
85. Isung J., Mobarrez F., Nordstrom P., Asberg M., Jokinen J. Low plasma vascular endothelial growth factor (VEGF) associated with completed suicide. World J. Biol. Psychiatry 2011, 13(6):468-473.
86. Jaerve A., Muller H.W. Chemokines in CNS injury and repair. Cell Tissue Res. 2012, 349:229-248.
87. Janelidze S., Ventorp F., Erhardt S., Hansson O., Minthon L., Flax J., Samuelsson M., Traskman-Bendz L., Brundin L. Altered chemokine levels in the cerebrospinal fluid and plasma of suicide attempters. Psychoneuroendocrinology 2013, 38:853-862.
88. Ji J.F., He B.P., Dheen S.T., Tay S.S. Expression of chemokine receptors CXCR4, CCR2, CCR5 and CX3CR1 in neural progenitor cells isolated from the subventricular zone of the adult rat brain. Neurosci. Lett. 2004, 355:236-240.
89. Johnson E.A., Dao T.L., Guignet M.A., Geddes C.E., Koemeter-Cox A.I., Kan R.K. Increased expression of the chemokines CXCL1 and MIP-1alpha by resident brain cells precedes neutrophil infiltration in the brain following prolonged soman-induced status epilepticus in rats. J. Neuroinflammation 2011, 8:41.
90. Jones C.A., Watson D.J., Fone K.C. Animal models of schizophrenia. Br. J. Pharmacol. 2011, 164:1162-1194.
91. Kaminska T., Wysocka A., Marmurowska-Michalowska H., Dubas-Slemp H., Kandefer-Szerszen M. Investigation of serum cytokine levels and cytokine production in whole blood cultures of paranoid schizophrenic patients. Arch. Immunol. Ther. Exp. (Warsz) 2001, 49:439-445.
92. Kamiya A., Sedlak T.W., Pletnikov M.V. DISC1 pathway in brain development: exploring therapeutic targets for major psychiatric disorders. Front. Psychiatr. 2012, 3:25.
93. Kan A.A., van der Hel W.S., Kolk S.M., Bos I.W., Verlinde S.A., van Nieuwenhuizen O., de Graan P.N. Prolonged increase in rat hippocampal chemokine signalling after status epilepticus. J. Neuroimmunol. 2012, 245:15-22.
94. Kapur S., Phillips A.G., Insel T.R. Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it?. Mol. Psychiatry 2012, 17:1174-1179.
95. Kelland E.E., Gilmore W., Weiner L.P., Lund B.T. The dual role of CXCL8 in human CNS stem cell function: multipotent neural stem cell death and oligodendrocyte progenitor cell chemotaxis. Glia 2011, 59:1864-1878.
96. Kester M.I., van der Flier W.M., Visser A., Blankenstein M.A., Scheltens P., Oudejans C.B. Decreased mRNA expression of CCL5 [RANTES] in Alzheimer's disease blood samples. Clin. Chem. Lab. Med. 2012, 50:61-65.
97. Khorram Khorshid H.R., Manoochehri M., Nasehi L., Ohadi M., Rahgozar M., Kamali R. Ccr2-64i and Ccr5 Delta32 polymorphisms in patients with late-onset Alzheimer's disease; a study from Iran (Ccr2-64i And Ccr5 Delta32 polymorphisms in Alzheimer's disease). Iran. J. Basic Med. Sci. 2012, 15:937-944.
98. Kim J.M., Stewart R., Kim S.W., Kim S.Y., Bae K.Y., Kang H.J., Jang J.E., Shin I.S., Yoon J.S. Physical health and incident late-life depression: modification by cytokine genes. Neurobiol. Aging 2013, 34(356):e351-e359.
99. Kim S.K., Ban J.Y., Park H.J., Chung J.H., Kim J.W. Lack of association between chemokine (C-C motif) receptor 3 (CCR3) gene and schizophrenia in the Korean population. Psychiatry Clin. Neurosci. 2010, 64:587-588.
100. Kim S.M., Song J., Kim S., Han C., Park M.H., Koh Y., Jo S.A., Kim Y.Y. Identification of peripheral inflammatory markers between normal control and Alzheimer's disease. BMC Neurol. 2011, 11:51.
101. Kim T.S., Lim H.K., Lee J.Y., Kim D.J., Park S., Lee C., Lee C.U. Changes in the levels of plasma soluble fractalkine in patients with mild cognitive impairment and Alzheimer's disease. Neurosci. Lett. 2008, 436:196-200.
102. Kipnis J., Gadani S., Derecki N.C. Pro-cognitive properties of T cells. Nat. Rev. Immunol. 2012, 12:663-669.
103. Koenig J.I., Kirkpatrick B., Lee P. Glucocorticoid hormones and early brain development in schizophrenia. Neuropsychopharmacology 2002, 27:309-318.
104. Krstic D., Knuesel I. Deciphering the mechanism underlying late-onset Alzheimer disease. Nat. Rev. Neurol. 2013, 9:25-34.
105. Lalor S.J., Segal B.M. Lymphoid chemokines in the CNS. J. Neuroimmunol. 2010, 224:56-61.
106. Laske C., Stellos K., Eschweiler G.W., Leyhe T., Gawaz M. Decreased CXCL12 (SDF-1) plasma levels in early Alzheimer's disease: a contribution to a deficient hematopoietic brain support?. J. Alzheimer Dis. 2008, 15:83-95.
107. Lee K.S., Chung J.H., Lee K.H., Shin M.J., Oh B.H., Hong C.H. Bioplex analysis of plasma cytokines in Alzheimer's disease and mild cognitive impairment. Immunol. Lett. 2008, 121:105-109.
108. Lehto S.M., Niskanen L., Herzig K.H., Tolmunen T., Huotari A., Viinamaki H., Koivumaa-Honkanen H., Honkalampi K., Ruotsalainen H., Hintikka J. Serum chemokine levels in major depressive disorder. Psychoneuroendocrinology 2010, 35:226-232.
109. Leyhe T., Hoffmann N., Stransky E., Laske C. Increase of SCF plasma concentration during donepezil treatment of patients with early Alzheimer's disease. Int. J. Neuropsychopharmacol. 2009, 12:1319-1326.
110. Licinio J. Translational Psychiatry: leading the transition from the cesspool of devastation to a place where the grass is really greener. Transl. Psychiatry 2011, 1:e1.
111. Lindqvist D., Janelidze S., Erhardt S., Traskman-Bendz L., Engstrom G., Brundin L. CSF biomarkers in suicide attempters-a principal component analysis. Acta Psychiatr. Scand. 2011, 124:52-61.
112. Lindqvist D., Janelidze S., Hagell P., Erhardt S., Samuelsson M., Minthon L., Hansson O., Bjorkqvist M., Traskman-Bendz L., Brundin L. Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biol. Psychiatry 2009, 66:287-292.
113. Liu J.X., Cao X., Tang Y.C., Liu Y., Tang F.R. CCR7, CCR8, CCR9 and CCR10 in the mouse hippocampal CA1 area and the dentate gyrus during and after pilocarpine-induced status epilepticus. J. Neurochem. 2007, 100:1072-1088.
114. Louboutin J.P., Strayer D.S. Relationship between the chemokine receptor CCR5 and microglia in neurological disorders: consequences of targeting CCR5 on neuroinflammation, neuronal death and regeneration in a model of epilepsy. CNS Neurol. Disord. Drug Targets 2013, 12:815-829.
115. Maes M. Targeting cyclooxygenase-2 in depression is not a viable therapeutic approach and may even aggravate the pathophysiology underpinning depression. Metab. Brain Dis. 2012, 27:405-413.
116. Maes M., Bocchio Chiavetto L., Bignotti S., Battisa Tura G.J., Pioli R., Boin F., Kenis G., Bosmans E., de Jongh R., Altamura C.A. Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor. Schizophr. Res. 2002, 54:281-291.
117. Maes M., Song C., Lin A.H., Pioli R., Kenis G., Kubera M., Bosmans E. In vitro immunoregulatory effects of lithium in healthy volunteers. Psychopharmacology (Berl.) 1999, 143:401-407.
118. Magaki S., Mueller C., Dickson C., Kirsch W. Increased production of inflammatory cytokines in mild cognitive impairment. Exp. Gerontol. 2007, 42:233-240.
119. Marksteiner J., Kemmler G., Weiss E.M., Knaus G., Ullrich C., Mechtcheriakov S., Oberbauer H., Auffinger S., Hinterholzl J., Hinterhuber H., Humpel C. Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease. Neurobiol. Aging 2011, 32:539-540.
120. Mathers C., Fat D.M. The Global Burden of Disease: 2004 Update 2008, 28-37. World Health Organisation, Geneva.
121. Mattsson N., Tabatabaei S., Johansson P., Hansson O., Andreasson U., Mansson J.E., Johansson J.O., Olsson B., Wallin A., Svensson J., Blennow K., Zetterberg H. Cerebrospinal fluid microglial markers in Alzheimer's disease: elevated chitotriosidase activity but lack of diagnostic utility. Neuromol. Med. 2011, 13:151-159.
122. McAfoose J., Baune B.T. Evidence for a cytokine model of cognitive function. Neurosci. Biobehav. Rev. 2009, 33:355-366.
123. Melik-Parsadaniantz S., Rostene W. Chemokines and neuromodulation. J. Neuroimmunol. 2008, 198:62-68.
124. Meng S.Z., Oka A., Takashima S. Developmental expression of monocyte chemoattractant protein-1 in the human cerebellum and brainstem. Brain Dev. 1999, 21:30-35.
125. Merendino R.A., Di Pasquale G., De Luca F., Di Pasquale L., Ferlazzo E., Martino G., Palumbo M.C., Morabito F., Gangemi S. Involvement of fractalkine and macrophage inflammatory protein-1 alpha in moderate-severe depression. Mediators Inflamm. 2004, 13:205-207.
126. Meucci O., Fatatis A., Simen A.A., Bushell T.J., Gray P.W., Miller R.J. Chemokines regulate hippocampal neuronal signaling and gp120 neurotoxicity. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:14500-14505.
127. Meyer U. Anti-inflammatory signaling in schizophrenia. Brain Behav. Immun. 2011, 25:1507-1518.
128. Miller A.H. Depression and immunity: a role for T cells?. Brain Behav. Immun. 2010, 24:1-8.
129. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 2011, 70:663-671.
130. Miller R.J., Rostene W., Apartis E., Banisadr G., Biber K., Milligan E.D., White F.A., Zhang J. Chemokine action in the nervous system. J. Neurosci. 2008, 28:11792-11795.
131. Moghaddam B., Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology 2012, 37:4-15.
132. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int. J. Surg. 2010, 8:336-341.
133. Muller N., Myint A.M., Schwarz M.J. Inflammation in schizophrenia. Adv. Protein Chem. Struct. Biol. 2012, 88:49-68.
134. Muller N., Schwarz M.J. Immune system and Schizophrenia. Curr. Immunol. Rev. 2010, 6:213-220.
135. Muller N., Schwarz M.J., Dehning S., Douhe A., Cerovecki A., Goldstein-Muller B., Spellmann I., Hetzel G., Maino K., Kleindienst N., Moller H.J., Arolt V., Riedel M. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol. Psychiatry 2006, 11:680-684.
136. Mundo E., Altamura A.C., Vismara S., Zanardini R., Bignotti S., Randazzo R., Montresor C., Gennarelli M. MCP-1 gene (SCYA2) and schizophrenia: a case-control association study. Am. J. Med. Genet. B: Neuropsychiatric Genet. 2005, 132B:1-4.
137. Murphy P.M., Baggiolini M., Charo I.F., Hebert C.A., Horuk R., Matsushima K., Miller L.H., Oppenheim J.J., Power C.A. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol. Rev. 2000, 52:145-176.
138. Musselman D.L., Marzec U.M., Manatunga A., Penna S., Reemsnyder A., Knight B.T., Baron A., Hanson S.R., Nemeroff C.B. Platelet reactivity in depressed patients treated with paroxetine: preliminary findings. Arch. Gen. Psychiatry 2000, 57:875-882.
139. Nakatani N., Hattori E., Ohnishi T., Dean B., Iwayama Y., Matsumoto I., Kato T., Osumi N., Higuchi T., Niwa S., Yoshikawa T. Genome-wide expression analysis detects eight genes with robust alterations specific to bipolar I disorder: relevance to neuronal network perturbation. Hum. Mol. Genet. 2006, 15:1949-1962.
140. Nguyen D., Hopfner M., Zobel F., Henke U., Scherubl H., Stangel M. Rat oligodendroglial cell lines express a functional receptor for the chemokine CCL3 (macrophage inflammatory protein-1alpha). Neurosci. Lett. 2003, 351:71-74.
141. Nikkila H.V., Ahokas A., Wahlbeck K., Rimon R., Andersson L.C. Neopterin and macrophage inflammatory protein-1alpha in the cerebrospinal fluid of schizophrenic patients: no evidence of intrathecal inflammation. Neuropsychobiology 2002, 46:169-172.
142. O'Brien S.M., Scully P., Dinan T.G. Increased tumor necrosis factor-alpha concentrations with interleukin-4 concentrations in exacerbations of schizophrenia. Psychiatry Res. 2008, 160:256-262.
143. O'Brien S.M., Scully P., Fitzgerald P., Scott L.V., Dinan T.G. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J. Psychiatr. Res. 2007, 41:326-331.
144. O'Brien S.M., Scully P., Scott L.V., Dinan T.G. Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J. Affect. Disord. 2006, 90:263-267.
145. Omari K.M., John G.R., Sealfon S.C., Raine C.S. CXC chemokine receptors on human oligodendrocytes: implications for multiple sclerosis. Brain 2005, 128:1003-1015.
146. Pace T.W., Miller A.H. Cytokines and glucocorticoid receptor signaling. Ann. N. Y. Acad. Sci. 2009, 1179:86-105.
147. Padmos R.C., Hillegers M.H., Knijff E.M., Vonk R., Bouvy A., Staal F.J., de Ridder D., Kupka R.W., Nolen W.A., Drexhage H.A. A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. Arch. Gen. Psychiatry 2008, 65:395-407.
148. Pae C.U., Chung K.I., Kim J.J., Yu H.S., Lee C.U., Lee S.J., Lee C., Jun T.Y., Serretti A., Paik I.H. Monocyte chemoattractant protein-1 promoter-2518 polymorphism and schizophrenia in the Korean population. Psychiatr. Genet. 2004, 14:65-67.
149. Pae C.U., Kim J.J., Yu H.S., Lee C.U., Lee S.J., Jun T.Y., Lee C., Paik I.H. Monocyte chemoattractant protein-1 promoter-2518 polymorphism may have an influence on clinical heterogeneity of bipolar I disorder in the Korean population. Neuropsychobiology 2004, 49:111-114.
150. Pae C.U., Yu H.S., Kim T.S., Lee C.U., Lee S.J., Jun T.Y., Lee C., Serretti A., Paik I.H. Monocyte chemoattractant protein-1 (MCP1) promoter-2518 polymorphism may confer a susceptibility to major depressive disorder in the Korean population. Psychiatry Res. 2004, 127:279-281.
151. Passos G.F., Figueiredo C.P., Prediger R.D., Pandolfo P., Duarte F.S., Medeiros R., Calixto J.B. Role of the macrophage inflammatory protein-1alpha/CC chemokine receptor 5 signaling pathway in the neuroinflammatory response and cognitive deficits induced by beta-amyloid peptide. Am. J. Pathol. 2009, 175:1586-1597.
152. Pellicano M., Bulati M., Buffa S., Barbagallo M., Di Prima A., Misiano G., Picone P., Di Carlo M., Nuzzo D., Candore G., Vasto S., Lio D., Caruso C., Colonna-Romano G. Systemic immune responses in Alzheimer's disease: in vitro mononuclear cell activation and cytokine production. J. Alzheimer Dis. 2010, 21:181-192.
153. Piletz J.E., Halaris A., Iqbal O., Hoppensteadt D., Fareed J., Zhu H., Sinacore J., Devane C.L. Pro-inflammatory biomakers in depression: treatment with venlafaxine. World J. Biol. Psychiatry 2009, 10:313-323.
154. Podlipny J., Hess Z., Vrzalova J., Rosolova H., Beran J., Petrlova B. Lower serum levels of interleukin-6 in a population sample with symptoms of depression than in a population sample without symptoms of depression. Physiol. Res. 2010, 59:121-126.
155. Pola R., Flex A., Gaetani E., Proia A.S., Papaleo P., Di Giorgio A., Straface G., Pecorini G., Serricchio M., Pola P. Monocyte chemoattractant protein-1 (MCP-1) gene polymorphism and risk of Alzheimer's disease in Italians. Exp. Gerontol. 2004, 39:1249-1252.
156. Pollak D.D., Rey C.E., Monje F.J. Rodent models in depression research: classical strategies and new directions. Ann. Med. 2010, 42:252-264.
157. Porcellini E., Ianni M., Carbone I., Franceschi M., Licastro F. Monocyte chemoattractant protein-1 promoter polymorphism and plasma levels in Alzheimer's disease. Immun. Ageing 2013, 10:6.
158. Puma C., Danik M., Quirion R., Ramon F., Williams S. The chemokine interleukin-8 acutely reduces Ca(2+) currents in identified cholinergic septal neurons expressing CXCR1 and CXCR2 receptor mRNAs. J. Neurochem. 2001, 78:960-971.
159. Ragozzino D., Di Angelantonio S., Trettel F., Bertollini C., Maggi L., Gross C., Charo I.F., Limatola C., Eusebi F. Chemokine fractalkine/CX3CL1 negatively modulates active glutamatergic synapses in rat hippocampal neurons. J. Neurosci. 2006, 26:10488-10498.
160. Raison C.L., Miller A.H. Is depression an inflammatory disorder?. Curr. Psychiatry Rep. 2011, 13:467-475.
161. Rasmussen H.B., Timm S., Wang A.G., Soeby K., Lublin H., Fenger M., Hemmingsen R., Werge T. Association between the CCR5 32-bp deletion allele and late onset of schizophrenia. Am. J. Psychiatry 2006, 163:507-511.
162. Rathbun A.M., Reed G.W., Harrold L.R. The temporal relationship between depression and rheumatoid arthritis disease activity, treatment persistence and response: a systematic review. Rheumatology 2013, 52:1785-1794.
163. Razzoli M., Domenici E., Carboni L., Rantamaki T., Lindholm J., Castren E., Arban R. A role for BDNF/TrkB signaling in behavioral and physiological consequences of social defeat stress. Genes Brain Behav. 2011, 10:424-433.
164. Reale M., Iarlori C., Feliciani C., Gambi D. Peripheral chemokine receptors, their ligands, cytokines and Alzheimer's disease. J. Alzheimer Dis. 2008, 14:147-159.
165. Reale M., Patruno A., De Lutiis M.A., Pesce M., Felaco M., Di Giannantonio M., Di Nicola M., Grilli A. Dysregulation of chemo-cytokine production in schizophrenic patients versus healthy controls. BMC Neurosci. 2011, 12:13.
166. Reaux-Le Goazigo A., Van Steenwinckel J., Rostene W., Melik Parsadaniantz S. Current status of chemokines in the adult CNS. Prog. Neurobiol. 2013, 104:67-92.
167. Rezaie P., Trillo-Pazos G., Everall I.P., Male D.K. Expression of beta-chemokines and chemokine receptors in human fetal astrocyte and microglial co-cultures: potential role of chemokines in the developing CNS. Glia 2002, 37:64-75.
168. Rogers J.T., Morganti J.M., Bachstetter A.D., Hudson C.E., Peters M.M., Grimmig B.A., Weeber E.J., Bickford P.C., Gemma C. CX3CR1 deficiency leads to impairment of hippocampal cognitive function and synaptic plasticity. J. Neurosci. 2011, 31:16241-16250.
169. Roh M.S., Lee K.Y., Joo E.J., Lee N., Kim Y.S. No association of the MCP-1 promoter A-2518G polymorphism with bipolar disorder in the Korean population. Neurosci. Lett. 2007, 427:1-5.
170. Rostene W., Dansereau M.A., Godefroy D., Van Steenwinckel J., Reaux-Le Goazigo A., Melik-Parsadaniantz S., Apartis E., Hunot S., Beaudet N., Sarret P. Neurochemokines: a menage a trois providing new insights on the functions of chemokines in the central nervous system. J. Neurochem. 2011, 118:680-694.
171. Rostene W., Guyon A., Kular L., Godefroy D., Barbieri F., Bajetto A., Banisadr G., Callewaere C., Conductier G., Rovere C., Melik-Parsadaniantz S., Florio T. Chemokines and chemokine receptors: new actors in neuroendocrine regulations. Front. Neuroendocrinol. 2011, 32:10-24.
172. Rostene W., Kitabgi P., Parsadaniantz S.M. Chemokines: a new class of neuromodulator?. Nat. Rev. Neurosci. 2007, 8:895-903.
173. Schwartz M., Shechter R. Protective autoimmunity functions by intracranial immunosurveillance to support the mind: the missing link between health and disease. Mol. Psychiatry 2010, 15:342-354.
174. Schwarz E., Guest P.C., Rahmoune H., Harris L.W., Wang L., Leweke F.M., Rothermundt M., Bogerts B., Koethe D., Kranaster L., Ohrmann P., Suslow T., McAllister G., Spain M., Barnes A., van Beveren N.J., Baron-Cohen S., Steiner J., Torrey F.E., Yolken R.H., Bahn S. Identification of a biological signature for schizophrenia in serum. Mol. Psychiatry 2012, 17:494-502.
175. Sery O., Povova J., Misek I., Pesak L., Janout V. Molecular mechanisms of neuropathological changes in Alzheimer's disease: a review. Folia neuropathologica/Association of Polish Neuropathologists and Medical Research Centre. Pol. Acad. Sci. 2013, 51:1-9.
176. Shelton R.C., Claiborne J., Sidoryk-Wegrzynowicz M., Reddy R., Aschner M., Lewis D.A., Mirnics K. Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. Mol. Psychiatry 2011, 16:751-762.
177. Simon N.M., McNamara K., Chow C.W., Maser R.S., Papakostas G.I., Pollack M.H., Nierenberg A.A., Fava M., Wong K.K. A detailed examination of cytokine abnormalities in Major Depressive Disorder. Eur. Neuropsychopharmacol. 2008, 18:230-233.
178. Skuljec J., Sun H., Pul R., Benardais K., Ragancokova D., Moharregh-Khiabani D., Kotsiari A., Trebst C., Stangel M. CCL5 induces a pro-inflammatory profile in microglia in vitro. Cell. Immunol. 2011, 270:164-171.
179. Soares H.D., Potter W.Z., Pickering E., Kuhn M., Immermann F.W., Shera D.M., Ferm M., Dean R.A., Simon A.J., Swenson F., Siuciak J.A., Kaplow J., Thambisetty M., Zagouras P., Koroshetz W.J., Wan H.I., Trojanowski J.Q., Shaw L.M., Biomarkers Consortium Alzheimer's Disease Plasma Proteomics P. Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. Arch. Neurol. 2012, 69:1310-1317.
180. Sokolova A., Hill M.D., Rahimi F., Warden L.A., Halliday G.M., Shepherd C.E. Monocyte chemoattractant protein-1 plays a dominant role in the chronic inflammation observed in Alzheimer's disease. Brain Pathol. 2009, 19:392-398.
181. Song C., Lin A., Bonaccorso S., Heide C., Verkerk R., Kenis G., Bosmans E., Scharpe S., Whelan A., Cosyns P., de Jongh R., Maes M. The inflammatory response system and the availability of plasma tryptophan in patients with primary sleep disorders and major depression. J. Affect. Disord. 1998, 49:211-219.
182. Spleiss O., Appel K., Boddeke H.W., Berger M., Gebicke-Haerter P.J. Molecular biology of microglia cytokine and chemokine receptors and microglial activation. Life Sci. 1998, 62:1707-1710.
183. Stuart M.J., Baune B.T. Depression and type 2 diabetes: inflammatory mechanisms of a psychoneuroendocrine co-morbidity. Neurosci. Biobehav. Rev. 2012, 36:658-676.
184. Suarez E.C., Krishnan R.R., Lewis J.G. The relation of severity of depressive symptoms to monocyte-associated proinflammatory cytokines and chemokines in apparently healthy men. Psychosom. Med. 2003, 65:362-368.
185. Suarez E.C., Lewis J.G., Krishnan R.R., Young K.H. Enhanced expression of cytokines and chemokines by blood monocytes to in vitro lipopolysaccharide stimulation are associated with hostility and severity of depressive symptoms in healthy women. Psychoneuroendocrinology 2004, 29:1119-1128.
186. Subileau E.A., Rezaie P., Davies H.A., Colyer F.M., Greenwood J., Male D.K., Romero I.A. Expression of chemokines and their receptors by human brain endothelium: implications for multiple sclerosis. J. Neuropathol. Exp. Neurol. 2009, 68:227-240.
187. Sun Y.X., Minthon L., Wallmark A., Warkentin S., Blennow K., Janciauskiene S. Inflammatory markers in matched plasma and cerebrospinal fluid from patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2003, 16:136-144.
188. Sutcigil L., Oktenli C., Musabak U., Bozkurt A., Cansever A., Uzun O., Sanisoglu S.Y., Yesilova Z., Ozmenler N., Ozsahin A., Sengul A. Pro- and anti-inflammatory cytokine balance in major depression: effect of sertraline therapy. Clin. Dev. Immunol. 2007, 76396.
189. Tagliari B., Tagliari A.P., Schmitz F., da Cunha A.A., Dalmaz C., Wyse A.T. Chronic variable stress alters inflammatory and cholinergic parameters in hippocampus of rats. Neurochem. Res. 2011, 36:487-493.
190. Teixeira A.L., Reis H.J., Nicolato R., Brito-Melo G., Correa H., Teixeira M.M., Romano-Silva M.A. Increased serum levels of CCL11/eotaxin in schizophrenia. Prog. Neuro-psychopharmacol. Biol. Psychiatry 2008, 32:710-714.
191. Tomppo L., Ekelund J., Lichtermann D., Veijola J., Jarvelin M.R., Hennah W. DISC1 conditioned GWAS for psychosis proneness in a large Finnish birth cohort. PLoS ONE 2012, 7:e30643.
192. Tran P.B., Banisadr G., Ren D., Chenn A., Miller R.J. Chemokine receptor expression by neural progenitor cells in neurogenic regions of mouse brain. J. Comp. Neurol. 2007, 500:1007-1033.
193. Tripathy D., Thirumangalakudi L., Grammas P. RANTES upregulation in the Alzheimer's disease brain: a possible neuroprotective role. Neurobiol. Aging 2010, 31:8-16.
194. Trollor J.N., Smith E., Baune B.T., Kochan N.A., Campbell L., Samaras K., Crawford J., Brodaty H., Sachdev P. Systemic inflammation is associated with MCI and its subtypes: the Sydney Memory and Aging Study. Dement. Geriatr. Cogn. Disord. 2010, 30:569-578.
195. Ubogu E.E., Cossoy M.B., Ransohoff R.M. The expression and function of chemokines involved in CNS inflammation. Trends Pharmacol. Sci. 2006, 27:48-55.
196. van Zuiden M., Heijnen C.J., van de Schoot R., Amarouchi K., Maas M., Vermetten E., Geuze E., Kavelaars A. Cytokine production by leukocytes of military personnel with depressive symptoms after deployment to a combat-zone: a prospective, longitudinal study. PLoS ONE 2011, 6:e29142.
197. Vendramini A.A., de Labio R.W., Rasmussen L.T., Dos Reis N.M., Minett T., Bertolucci P.H., de Souza Pinhel M.A., Souza D.R., Mazzotti D.R., de Arruda Cardoso Smith M., Payao S.L. Interleukin-8-251T>A, interleukin-1alpha-889C>T and apolipoprotein E polymorphisms in Alzheimer's disease. Genet. Mol. Biol. 2011, 34:1-5.
198. Vendramini A.A., de Labio R.W., Rasmussen L.T., Minett T., Bertolucci P.H., de Arruda Cardoso Smith M., Payao S.L. Interleukin-8 gene polymorphism -251T>A and Alzheimer's disease. J. Alzheimer Dis. 2007, 12:221-222.
199. Villa C., Venturelli E., Fenoglio C., Clerici F., Marcone A., Benussi L., Ghidoni R., Gallone S., Cortini F., Scalabrini D., Serpente M., Binetti G., Cappa S., Mariani C., Rainero I., Bresolin N., Scarpini E., Galimberti D. CCL8/MCP-2 association analysis in patients with Alzheimer's disease and frontotemporal lobar degeneration. J. Neurol. 2009, 256:1379-1381.
200. Vukovic J., Colditz M.J., Blackmore D.G., Ruitenberg M.J., Bartlett P.F. Microglia modulate hippocampal neural precursor activity in response to exercise and aging. J. Neurosci. 2012, 32:6435-6443.
201. Warner-Schmidt J.L., Vanover K.E., Chen E.Y., Marshall J.J., Greengard P. Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:9262-9267.
202. Weeraratna A.T., Kalehua A., Deleon I., Bertak D., Maher G., Wade M.S., Lustig A., Becker K.G., Wood W., Walker D.G., Beach T.G., Taub D.D. Alterations in immunological and neurological gene expression patterns in Alzheimer's disease tissues. Exp. Cell Res. 2007, 313:450-461.
203. Weiss N., Deboux C., Chaverot N., Miller F., Baron-Van Evercooren A., Couraud P.O., Cazaubon S. IL8 and CXCL13 are potent chemokines for the recruitment of human neural precursor cells across brain endothelial cells. J. Neuroimmunol. 2010, 223:131-134.
204. Westin K., Buchhave P., Nielsen H., Minthon L., Janciauskiene S., Hansson O. CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer's disease. PLoS ONE 2012, 7:e30525.
205. Whiteford H.A., Degenhardt L., Rehm J., Baxter A.J., Ferrari A.J., Erskine H.E., Charlson F.J., Norman R.E., Flaxman A.D., Johns N., Burstein R., Murray C.J., Vos T. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 2013, 382:1575-1586.
206. Widera D., Holtkamp W., Entschladen F., Niggemann B., Zanker K., Kaltschmidt B., Kaltschmidt C. MCP-1 induces migration of adult neural stem cells. Eur. J. Cell Biol. 2004, 83:381-387.
207. Wilberding A., Morimoto K., Satoh H., Harano K., Harano T., Arita S., Tooyama I., Konishi Y. Multiple cytokines are involved in the early events leading to the Alzheimer's disease pathology. Tottori Rinsho Kagaku Kenkyukai shi 2008, 1:359-373.
208. Willner P., Towell A., Sampson D., Sophokleous S., Muscat R. Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology (Berl.) 1987, 93:358-364.
209. Wilson C., Terry A.V. Neurodevelopmental animal models of schizophrenia: role in novel drug discovery and development. Clin. Schizoph. Relat. Psychoses 2010, 4:124-137.
210. Wong M.L., Dong C., Maestre-Mesa J., Licinio J. Polymorphisms in inflammation-related genes are associated with susceptibility to major depression and antidepressant response. Mol. Psychiatry 2008, 13:800-812.
211. Wu Y., Peng H., Cui M., Whitney N.P., Huang Y., Zheng J.C. CXCL12 increases human neural progenitor cell proliferation through Akt-1/FOXO3a signaling pathway. J. Neurochem. 2009, 109:1157-1167.
212. Yao Y., Schroder J., Karlsson H. Verification of proposed peripheral biomarkers in mononuclear cells of individuals with schizophrenia. J. Psychiatr. Res. 2008, 42:639-643.
213. Young J.W., Zhou X., Geyer M.A. Animal models of schizophrenia. Curr. Topics Behav. Neurosci. 2010, 4:391-433.
214. Zakharyan R., Boyajyan A., Arakelyan A., Melkumova M., Mrazek F., Petrek M. Monocyte chemoattractant protein-1 in schizophrenia: -2518A/G genetic variant and protein levels in Armenian population. Cytokine 2012, 58:351-354.
215. Zhang R., Miller R.G., Madison C., Jin X., Honrada R., Harris W., Katz J., Forshew D.A., McGrath M.S. Systemic immune system alterations in early stages of Alzheimer's disease. J. Neuroimmunol. 2013, 256:38-42.
216. Zhang X.Y., Cao L.Y., Song C., Wu G.Y., Chen da C., Qi L.Y., Wang F., Xiu M.H., Chen S., Zhang Y., Lu L., Kosten T.A., Kosten T.R. Lower serum cytokine levels in smokers than nonsmokers with chronic schizophrenia on long-term treatment with antipsychotics. Psychopharmacology (Berl.) 2008, 201:383-389.
217. Zhang X.Y., Zhou D.F., Zhang P.Y., Wu G.Y., Cao L.Y., Shen Y.C. Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology. Schizophr. Res. 2002, 57:247-258.
218. Ziats M.N., Rennert O.M. Identification of differentially expressed microRNAs across the developing human brain. Mol. Psychiatry 2013, [Epub ahead of print]. 10.1038/mp.2013.93.